SCHEDULE: BML Investment Partners Reports 0% Stake in Kezar Life Sciences

BML Investment Partners, L.P. has filed a Schedule 13G amendment indicating no beneficial ownership of Kezar Life Sciences, Inc. common stock as of May 11, 2026.

Summary

• BML Investment Partners, L.P. has filed an amendment to its Schedule 13G filing.
• The filing, dated May 11, 2026, indicates that BML Investment Partners, L.P. beneficially owns 0 shares of Kezar Life Sciences, Inc. common stock.
• This represents 0% of the class of securities.
• The reporting person has no sole or shared voting power or sole or shared power to dispose or direct the disposition of any shares.
• BML Investment Partners, L.P. is a Delaware limited partnership, with BML Capital Management, LLC as its sole general partner.
• Braden M. Leonard is the managing member of BML Capital Management, LLC and is deemed the indirect owner of shares held by BML Investment Partners, L.P., though no shares are currently held.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as having a low sentiment score due to the complete absence of beneficial ownership, indicating no current investment or positive outlook from the reporting entity.

Negatives

• BML Investment Partners, L.P. holds no shares in Kezar Life Sciences, Inc., indicating no current investment or strategic interest from this entity.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Management Comments

• "BML Investment Partners, L.P. is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC. The managing member of BML Capital Management, LLC is Braden M. Leonard. As a result, Braden M. Leonard is deemed to be the indirect owner of the shares held directly by BML Investment Partners, L.P. Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b)(1) of the Exchange Act."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are typically made by institutional investors who acquire beneficial ownership of more than 5% of a class of a company's registered equity securities. A filing indicating 0% ownership suggests a divestment or a lack of current investment by BML Investment Partners, L.P. in Kezar Life Sciences, Inc.

Key Dates

Keywords

Schedule 13G, Kezar Life Sciences, BML Investment Partners, Beneficial Ownership, SEC Filing, Securities Exchange Act